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Summary
African swine fever virus (ASFV) causes a lethal haemorrhagic disease of swine
which can be transmitted through direct contact with infected animals and their
excretions or indirect contact with contaminated fomites. The shedding of ASFV
by infected pigs and the stability of ASFV in the environment will determine the
extent of environmental contamination. The recent outbreaks of ASF in Europe
make it essential to develop disease transmission models in order to design effec-
tive control strategies to prevent further spread of ASF. In this study, we assessed
the shedding and stability of ASFV in faeces, urine and oral fluid from pigs
infected with the Georgia 2007/1 ASFV isolate. The half-life of infectious ASFV in
faeces was found to range from 0.65 days when stored at 4°C to 0.29 days when
stored at 37°C, while in urine it was found to range from 2.19 days (4°C) to
0.41 days (37°C). Based on these half-lives and the estimated dose required for
infection, faeces and urine would be estimated to remain infectious for 8.48 and
15.33 days at 4°C and 3.71 and 2.88 days at 37°C, respectively. The half-life of
ASFV DNA was 8 to 9 days in faeces and 2 to 3 days in oral fluid at all tempera-
tures. In urine, the half-life of ASFV DNA was found to be 32.54 days at 4°C
decreasing to 19.48 days at 37°C. These results indicate that ASFV in excretions
may be an important route of ASFV transmission.
Introduction
African swine fever virus (ASFV) is the cause of African
swine fever (ASF) a frequently lethal, haemorrhagic disease
of wild boar and domestic pigs. African swine fever is cur-
rently endemic in many African countries and Sardinia
(OIE, 2014). African swine fever was recently introduced
into the Trans Caucasus region, Russian Federation and
several countries in eastern Europe. This followed the
introduction of ASF, in 2007, to Georgia and subsequent
spread into surrounding countries including Armenia,
Azerbaijan and the Russian Federation (Beltran-Alcrudo
et al., 2008; Sabirovic et al., 2008). Between 2012 and 2013,
several outbreaks of ASF were reported in Ukraine and Bel-
arus (OIE, 2012–2013). From January 2014 until present
(April 2015), outbreaks of ASFV were detected in wild boar
and domestic pigs in Lithuania, Poland and Latvia and wild
boar in Estonia (OIE, 2014) marking the first outbreaks of
ASFV in the continental European Union since it was erad-
icated in 1995 (Arias et al., 2002). In Sardinia, ASF has
been endemic since its introduction in 1978 (Costard et al.,
2009). These recent events make it essential to develop
effective control strategies to prevent further spread of ASF
into Europe. A key part of this will be to develop indirect
and direct transmission models to facilitate the prediction
of disease spread.
Transmission can occur through direct contact
between sick and healthy animals or by contact with
infectious excretions and secretions. Indirect transmission
can also occur if healthy pigs ingest infected meat prod-
ucts or have contact with contaminated fomites (Mur
et al., 2012). Indirect transmission is important in the
spread of ASFV, for example the 2007 outbreak in Geor-
gia was thought to have been caused by the improper
disposal of infected pork from a ship at a Black Sea port
(Beltran-Alcrudo et al., 2008).
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In the current study, survival of ASFV in excretions from
pigs was examined using samples obtained from experi-
mental infection of pigs with the Georgia 2007/1 strain.
This information will also help determine the potential
diagnostic use of detecting ASFV DNA in excretions. In
previous studies with other ASFV isolates, it was found that
the inactivation of ASFV occurs more quickly in slurry than
in medium (Turner and Williams, 1999) because no infec-
tious virus was detected in slurry after 24 h at 4 or 22°C
(Turner et al., 1999). However, studies carried out in slurry
do not provide information on which excretions are likely
to contain infectious virus and how long the virus can sur-
vive in them. Another set of experiments using different
isolates found that faeces, urine and oral fluid collected
from ASFV-infected pigs can contain infective ASFV (Eus-
tace Montgomery, 1921; Greig and Plowright, 1970). It has
also been shown that ASFV in faeces can remain infective
for at least eleven days when kept in the dark at room tem-
perature (Eustace Montgomery, 1921). In a more recent
study,1 it was found that the half-life of ASFV in faeces was
1.7 days at 5°C and decreased to 0.2 days at 37°C. Faeces,
urine and oral fluid can easily contaminate water sources,
soil and animal pens. The assessment of the shedding and
stability of ASFV in these excretions will be important in
understanding the extent of environmental contamination
that can occur. In the current study, we assessed the sur-
vival of ASFV DNA and infectious virus in faeces, urine
and oral fluid from pigs infected with the Georgia 2007/1
isolate. Genome analysis of isolates obtained from the Rus-
sian Federation, Lithuania, Poland and Belarus indicated
these were very closely related to the Georgia 2007/1 isolate
(Malogolovkin et al., 2012; Gallardo et al., 2014). Thus, we
considered the Georgia 2007/1 isolate representative of
those isolates currently circulating in eastern Europe and
the Russian Federation.
Materials and Methods
Infection of pigs with ASFV and sample collection
Eight Landrace cross-domestic pigs were intramuscularly
infected with ASFV isolate Georgia 2007/1 with 1 9 102
50% haemadsorbing doses (HAD50). An equal number of
Landrace cross domestic pigs were placed in the same pen
to act as contacts. This experiment was primarily carried
out to assess the transmission of ASFV between infected
and healthy animals (Guinat et al., 2014).
Faecal and urine samples were collected during the
experiment, where possible, or during post-mortem. Oral
fluid was collected using cotton swabs which were incu-
bated in 1 ml phosphate-buffered saline (PBS) for 1 h.
Fluid was collected after vortexing and the swab discarded.
Oral fluid was also collected by pressing a rope, left in pens
for pigs to chew on, through a mangle. Twenty-six faecal
and fifteen urine samples were collected between 0 and
11 days post-infection (dpi). Twelve oral fluid samples, col-
lected on cotton swabs, were obtained between 1 and
10 dpi. Samples were stored at 80°C before being tested
by qPCR and virus titration for ASFV DNA and infectious
virus.
Processing of faeces
Faecal samples were separated into 500 mg aliquots and
stored for a maximum of 98 days at 4 and 12°C or for a
maximum of 70 days at room temperature (21–23°C) and
37°C. Samples were removed from storage at days 0, 1, 2, 3,
5, 7, 14, 21, 28, 35, 42, 70 or 98 depending on the availabil-
ity of samples. Samples were diluted 1 : 10 with Earle’s
saline salt solution supplemented with 2% Field Antibiotics
[1000 U/ml penicillin, 1 mg/ml streptomycin, 10 mg/ml
kanamycin and 20 mg/ml amphotericin B (Sigma-Aldrich,
St Loius, MO, USA)] and 5% pig serum. Faecal samples
were homogenized by vortexing with 1.4 mm ceramic
beads (MP Biomedicals, Santa Ana, CA, USA) and centri-
fuged at 2370 g for 10 min to remove debris (Weesendorp
et al., 2008). One millilitre of supernatant was removed
and placed in a fresh tube before centrifugation at 18 000 g
for 5 min to remove debris. The supernatants were individ-
ually analysed by virus titration and qPCR.
Processing of urine and oral fluid
Urine and oral fluid samples were separated into 500 ll
aliquots. Urine samples were stored for a maximum of
126 days at 4, 12, 21 or 37°C. Samples were removed from
storage on days 0, 1, 2, 3, 5, 7, 14, 21, 28, 35, 42, 70, 98 or
126 depending on the availability of samples. Due to the
small volume of oral fluid collected, all qPCR positive sam-
ples were mixed together. Oral fluid samples were stored
for a maximum of 35 days at 4°C, 28 days at 12°C or
21 days at 21 and 37°C. Samples were removed from stor-
age at days 0, 1, 2, 3, 5, 7, 14, 21, 28 or 35 depending on the
availability of samples. Two per cent Field Antibiotic was
added, and samples were centrifuged for 5 min at 18 000 g
to remove debris. Supernatants were analysed for the pres-
ence of infectious ASFV and virus genome by virus titration
and qPCR.
Virus titrations
Virus titrations were carried out using pulmonary alveolar
macrophages (PAMs) collected by lung lavage from unin-
fected pigs. Pulmonary alveolar macrophages were seeded
at 1 9 105 cells per well in a 96-well plate. Fifty microlitres
of sample supernatant was serially diluted seven times at a
1 : 10 dilution in Earle’s saline salt solution. Hundred
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microlitres of each dilution was used to inoculate each of 3
wells of a 96-well plate to obtain triplicate values. African
swine fever virus Georgia 2007/1 was used as a positive con-
trol, and Earle’s saline salt solution was used as a negative
control. Plates were incubated at 37°C for 3 days.
Infected cells were identified by immunofluorescence
using a monoclonal antibody against ASFV p30 protein.
Medium was removed from each well, and cells were
washed with PBS. Cells were fixed by immersing in 4%
paraformaldehyde for 1 h at room temperature and then
washed with PBS. Cells were permeabilized with 100 ll
PBS + 0.2% Triton X-100 per well for 5 min at room tem-
perature and then washed with PBS. Cells were incubated
with monoclonal antibody anti-P30 (C18) diluted 1 : 3000
in PBS containing 1% bovine serum albumin (BSA) for 1 h
at room temperature and then washed with PBS. Cells were
incubated with anti-mouse Alexa Fluor 488 diluted 1 : 500
in PBS containing 1% BSA for 1 h at room temperature
and then washed with PBS. Plates were viewed under a
fluorescent microscope, and the virus titre was determined
using the Spearman–K€arber formula. The detection thresh-
old for faeces was determined as 1 9 102.83 TCID50/g (50%
tissue culture infectious doses) and for urine and oral fluid
was 1 9 101.83 TCID50/ml. The difference in the thresholds
is due to the fact that the faeces samples had to be diluted
in medium before processing, while urine was used without
dilution.
DNA extraction and quantitative PCR (qPCR)
DNA was extracted from 100 ll of sample supernatant
using the KingFisher Flex Extraction System (Thermo Sci-
entific) using the MagVetTM Universal Isolation Kit (Life
Technologies) following protocol NM_LSI_RRC96. Each
extraction was carried out in duplicate and contained ASFV
Georgia 2007/1 as a positive control and PBS as a negative
control. Extracted DNA was stored at 4°C until it could be
analysed by qPCR. qPCR was carried out on a Stratagene
Mx3005P (Agilent Technologies, Santa Clara, CA, USA)
following a protocol modified from King et al., 2003 as
described by King et al., 2011. A standard curve was con-
structed by the serial dilution of control plasmid, and gen-
ome copies were calculated from the standard curve based
on the cycle threshold (Ct) values. Ct values >40 were con-
sidered negative.
Statistical analysis
Significant differences between the average viral titre
detected in blood samples collected from animals on days
that they were positive or negative for infectious ASFV or
ASFV genome in faecal, urine or oral fluid samples were
tested with two-way ANOVA followed by Sidak’s multiple
comparisons tests using GraphPad Prism version 6.00 for
Windows (GraphPad Software, La Jolla, CA, USA,
www.graphpad.com).
The survival of viable ASFV assayed by virus titration
was analysed using the R statistical software using packages
‘MASS’ and ‘survival’ (R-Core-Team). Log-transformed
virus titres were used to create a linear mixed model with
sample as random effect and temperature as a continuous
variable. The detection threshold was incorporated in the
analysis by left-censoring those observations in which the
level of virus was below the detection threshold.
The survival of ASFV DNA assayed by qPCR was analy-
sed using the R statistical software using packages ‘MASS’
and ‘nlme’ (R-Core-Team). Log-transformed virus titres
were used to create a linear mixed model fit by maximum
likelihood, with sample as random effect and temperature
as a continuous variable. Half-life of viable ASFV and ASFV
DNA was calculated from the models using the formula:
Half-life = log(2)/slope. All samples that were positive
for ASFV infectious virus were also positive for ASFV
DNA.
Results
Detection of ASFV in excretions from infected pigs
As shown in Table 1, 2/26 faecal samples, 5/15 urine sam-
ples and 5/12 oral fluid samples collected, tested positive
for ASFV DNA by qPCR. From these, 2/26 faecal samples
and 3/15 urine samples were positive for infectious ASFV.
However, no oral fluid samples were positive by virus titra-
tion for infectious ASFV. Faecal samples that were positive
for infectious ASFV and ASFV DNA were detected from
the first day of fever (>40°C). One urine sample was posi-
tive for ASFV DNA the day prior to the onset of fever, but
Table 1. Number of samples collected of each sample type on days rel-
ative to the onset of pyrexia in infected pigs. The total number of sam-
ples collected of faeces, urine and oral fluid relative to the onset of
fever in infected pigs is shown. These samples were tested by quantita-
tive PCR (qPCR) and virus titration (VT) and the day that the samples
tested positive for ASFV are also shown relative to the onset of pyrexia
Sample type
Onset of Pyrexia (days)
Total1 0 1 2 3
Samples collected Faeces 4 6 9 6 1 26
Urine 2 4 5 4 – 15
Oral fluid – 3 5 4 – 12
qPCR positive Faeces – 1 – 1 – 2
Urine 1 2 1 1 – 5
Oral fluid – 2 2 1 – 5
VT positive Faeces – 1 – 1 – 2
Urine – 2 – 1 – 3
Oral fluid – – – – – –
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infectious ASFV was only detected in urine from the first
day of fever. In oral fluid, ASFV DNA was detected in sam-
ples from the start of fever.
To assess whether a higher viraemia was associated with
a higher probability of collecting positive excretions, the
average viral titre detected in blood samples (Guinat et al.,
2014) collected from animals on days that they were either
positive or negative for infectious ASFV or ASFV genome
in faecal, urine or oral fluid samples was compared. The
average virus titre in blood on the same day as faecal sam-
ples that were negative for ASFV DNA (n = 22) was
5.75 9 106 and for those faecal samples that were positive
for ASFV DNA (n = 2) was 4.96 9 106. Average virus titres
in blood were 8.88 9 106 for urine samples (n = 10) that
were negative for ASFV and 4.36 9 106 for urine samples
(n = 4) that were positive for ASFV. Differences in virus
titres in blood for those faecal and urine samples that were
positive for ASFV compared to those that were negative
were not significant (P ≥ 0.1).
Survival of infectious ASFV in excretions
The survival of infectious ASFV in faeces and urine at dif-
ferent temperatures is shown in Figure S1. Infectious ASFV
could be detected for up to 5 days at 4°C and 12°C, 3 days
at 21°C and 1 day at 37°C in faeces (Figure S1). In urine,
infectious ASFV could be detected for up to 5 days at 4°C,
12°C and 21°C and 1 day at 37°C (Figure S1). The half-life
of infectious ASFV in faeces and urine at different tempera-
tures is shown in Table 2. The effect of temperature on the
survival of ASFV in faeces and urine over time was statisti-
cally significant (P < 0.001).
Experimental infections with the moderately virulent
Kenyan ASFV isolate Ken05/Tk1 showed that inoculation
with 10 HAD50 (equivalent to TCID50) via the intramuscu-
lar route or oro-nasal route resulted in ASF disease in all
inoculated pigs. Similarly, immunization of pigs with 10
HAD50 of the Armenian ASFV isolate Arm07 via the intra-
muscular route resulted in all inoculated pigs developing
ASF disease (Gallardo et al., 2013). The Arm07 isolate is
closely related to the Georgia 2007/1 isolate used in this
study. Therefore, 10 HAD50 was estimated to be the mini-
mum infectious dose for the Georgia 2007/1 strain. The
estimated duration of survival of viable ASFV above this
infectious dose was calculated using the half-life value and
the mean initial viral titre. The mean initial titre of faecal
samples was 1 9 104.83 TCID50/g, and the mean initial titre
of urine samples was 1 9 102.94 TCID50/ml. The estimated
duration of survival of infectious ASFV is shown in
Table 3. With these initial titres, infectious ASFV can be
estimated to survive in faeces from 8.5 days at 4°C to
3.7 days at 37°C and around 15.3 days at 4°C to 2.9 days
at 37°C in urine.
Survival of ASFV DNA in excretions
The mean initial titre of ASFV in faeces was 1 9 106.52 gen-
ome copies per gram. In urine, the mean initial titre of
ASFV was 1 9 104.38 genome copies per ml and for oral
fluid the initial titre of ASFV was 1 9 104.72 genome cop-
ies per ml. The survival of ASFV DNA in faeces, urine and
oral fluid can be seen in Figure S2. In faeces, ASFV DNA
could be detected up to at least day 98 at 4°C and 12°C
and up to 35 days at 21°C and 37°C (Figure S2). In urine,
Table 2. Half-life of viable ASFV and ASFV DNA in excretions at different temperatures. Half-life of viable ASFV and ASFV DNA in faeces, urine and
oral fluid stored at 4, 12, 21 and 37°C
Half-life of ASFV (days)
Sample type
Virus titration
Number
Samples
Tested
qPCR
Number
Samples
Tested
Temperature Temperature
4°C 12°C 21°C 37°C 4°C 12°C 21°C 37°C
Faeces 0.65 0.50 0.39 0.29 2 9.95 9.48 9.00 8.25 2
Urine 2.19 1.07 0.68 0.41 3 32.54 27.99 24.18 19.48 5
Oral fluid – – – – – 2.75 2.72 2.67 2.60 5
Table 3. Estimated duration of survival of infectious ASFV in excretions
at different temperatures. Estimated duration of survival of infectious
ASFV in faeces, urine and oral fluid stored at 4, 12, 21 and 37°C, calcu-
lated assuming an infectious dose of 10 HAD50 initial mean viral titre of
each sample type and half-life value (Table 2) for each sample type at 4,
12, 21 and 37°C
Estimated survival of ASFV (days)
Sample type
Viable ASFV
Mean initial
titre (TCID50)
Temperature
4°C 12°C 21°C 37°C
Faeces 1 9 104.83 8.5 6.5 5.1 3.7
Urine 1 9 102.94 15.3 7.5 4.8 2.9
Oral Fluid – – – – –
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ASFV DNA could be detected for at least 126 days at all
temperatures (Figure S2). In oral fluid, ASFV DNA could
be detected for 35 days at 4°C, 14 days at 12°C and 21°C.
No ASFV DNA could be detected in oral fluid after storage
at 37°C (Figure S2). The half-life of ASFV DNA in faeces,
urine and oral fluid can be seen in Table 3. The effect of
temperature on the on the survival of ASFV DNA in
urine faeces and oral fluid was statistically significant
(P < 0.001).
Discussion
This study assessed the shedding and survival of infectious
ASFV and ASFV DNA in excretions collected from pigs
infected with Georgia 2007/1 isolate. The shedding of ASFV
in excretions begins at approximately the same time as the
onset of fever. This was also observed in a previous study in
which infected faeces were detected from the onset of fever
(Greig and Plowright, 1970) or the onset of other clinical
signs (de Carvalho Ferreira et al., 2012). Detection of ASFV
DNA in blood is usually correlated with onset of clinical
signs. To determine whether high viral titre in blood
increased the chance of collecting excretion samples positive
for ASFV genome or virus, the average viral titre detected in
blood samples (Guinat et al., 2014) collected from animals
on days that they were positive or negative for infectious
ASFV or ASFV genome in excretions was compared. As no
significant difference was obtained, this suggests that the
level of viraemia has no effect on the production of infec-
tious excretions. Possibly levels of replication in tissues in
the local area may be an important factor.
Only one urine sample positive for ASFV was obtained
outside of this period, the day before the start of fever. This
animal had reached the humane end point the day after the
positive sample was collected and was culled.
The half-life for ASFV in urine was shown to be longer
than the half-life in faeces and oral fluid for both infectious
virus and viral DNA, suggesting urine is the most stable
medium tested for ASFV survival. Differences in survival
times for infectious virus may result from the relative levels
of enzymes, including proteases or lipases, which inactivate
virus in the different samples. These enzymes may be
derived from bacteria present. The half-life for ASFV DNA
in excretions is much longer than the half-life for viable
ASFV. Thus, the detection of ASFV DNA does not always
predict the detection of infectious ASFV, but may confirm
an infected population.
The collection of unpreserved field faecal samples as an
alternative non-invasive surveillance method of wild boar
and free-ranging pigs has been suggested as the survival of
ASFV DNA in faeces can be long even at temperatures
above room temperature1 (de Carvalho Ferreira et al.,
2014). In a previous study, ASFV was detected in 53% of
faecal samples from pigs infected with the highly virulent
Brazil’78 ASFV isolate (de Carvalho Ferreira et al., 2014).
However, in the present experiment, only 8.7% of the fae-
ces collected from viraemic animals were positive. This sug-
gests that the analysis of faecal samples would not be a
sensitive method to use in the surveillance for strains of
ASFV from eastern Europe, the Russian Federation or
Trans Caucasus region in wild boar or free-ranging pig
populations. This observation suggests there may be differ-
ences in the pathogenesis resulting from infection with the
Georgia 2007/1 isolate compared to the Brazil’78 isolate
that may result in more frequent excretion of infectious
virus in faeces from Brazil’78 isolate.
Half-live values obtained in previous studies for survival
of viable ASFV in faeces are similar to those observed in
the present study. However, the half-life value at lower
temperatures was slightly longer, 1.7 days at 5°C in the
previous study compared to 0.65 days at 4°C in the cur-
rent study. The half-life values for ASFV DNA in urine
and faeces were also obtained previously and showed a
greater stability of ASFV DNA in faeces and less stability
of ASFV DNA in urine compared to observations in the
present study.
Previously faecal samples collected from ASFV-infected
pigs were found to be infectious after storage at room
temperature for 11 days (Eustace Montgomery, 1921). In
the present study, faecal samples were estimated to
remain infective for 5.1 days at room temperature. This
difference may be due to the fact that the samples in the
previous study were kept in the dark which may provide
protection from damage caused to the virus by ultraviolet
light.
The detection of viral DNA but no viable virus in
oral fluid samples may have been due to the titre of
infectious virus being lower than the detection threshold
of the virus isolation test used. Viable virus was previ-
ously detected in saliva at 100.9 HAD50/ml (Greig and
Plowright, 1970), below the detection threshold for the
method used in the present study. Viral DNA found on
swabs may also have been due to residual contamination
of the pig’s mouth.
Only a relatively small proportion of samples collected
contained infectious ASFV. However, as the infectious dose
of ASFV via the oro-nasal route was estimated to be 10
HAD50 (Gallardo et al., 2013), even a small amount of
infective material could lead to transmission. Infectious
material could be transported to other pens or farms on
clothing, footwear, equipment and machinery. Faeces and
urine can easily contaminate food and water sources for
other animals in the same pen. It can therefore be con-
cluded that the excretion of ASFV in the faeces and urine of
infected pigs may be an important route of transmission of
ASFV between domestic pigs.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Survival of Infectious ASFV in faeces and
urine stored at different temperatures. Graphs show the
survival of infectious ASFV in faeces stored at different
temperatures (Panel a, b, c, d), The red line represents the
detection threshold at 1 9 102.83 TCID50/g and the survival
of infectious ASFV in urine (Panel e, f, g, h), with the black
line representing the detection threshold at 1 9 101.83
TCID50/ml.
Figure S2. Survival of ASFV DNA in excretions stored at
different temperatures. Graphs show the survival of ASFV
DNA in faeces (Panels a, b, c, d), the survival of ASFV
DNA in urine (Panel e, f, g, h) and the survival of ASFV
DNA in oral fluid (Panel i, j, k, l) stored at 4°C (Panels a, e,
i), 12°C (Panels b, f, j), 21°C (Panels c, g, k) and 37°C
(Panels d, h, l).
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